See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

AusperBio Receives China CDE Clearance to Advance AHB-137 into Phase III Clinical Trial for Chronic Hepatitis B

Summary by Helena Independent Record
SAN FRANCISCO, July 21, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company advancing targeted oligonucleotide therapies for chronic hepatitis B (CHB) functional cure, today announced that the China Center for Drug…

19 Articles

Helena Independent RecordHelena Independent Record
+18 Reposted by 18 other sources
Center

AusperBio Receives China CDE Clearance to Advance AHB-137 into Phase III Clinical Trial for Chronic Hepatitis B

SAN FRANCISCO, July 21, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company advancing targeted oligonucleotide therapies for chronic hepatitis B (CHB) functional cure, today announced that the China Center for Drug…

·Helena, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 89% of the sources are Center
89% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Helena Independent Record broke the news in Helena, United States on Monday, July 21, 2025.
Sources are mostly out of (0)

Similar News Topics

China icon

China

News
For You
SearchBlindspotLocal